Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a Huntingtin (HTT) gene, as well as methods of inhibiting expression of an HTT gene and methods of treating subjects having an HTT-associated disease or disorder, e.g., Huntington's disease, using such dsRNAi agents and compositions.
Type:
Grant
Filed:
June 1, 2023
Date of Patent:
May 28, 2024
Assignee:
Alnylam Pharmaceuticals, Inc.
Inventors:
Mangala Meenakshi Soundarapandian, James D. McIninch, Mark K. Schlegel, Adam Castoreno
Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
Abstract: Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
Type:
Grant
Filed:
September 27, 2022
Date of Patent:
May 28, 2024
Assignee:
Rigel Pharmaceuticals, Inc.
Inventors:
Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
Abstract: Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.
Abstract: Disclosed herein are compounds of the formula: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to modulate the activity of IL-17 and ROR?. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or for autoimmune disorders.
Type:
Grant
Filed:
June 17, 2019
Date of Patent:
May 28, 2024
Assignee:
REATA PHARMACEUTICALS, INC
Inventors:
Xin Jiang, Melean Visnick, Christopher F. Bender, Gary Bolton, Bradley Caprathe, Chitase Lee, Brian Kornberg, Patrick O'Brien, Martha R. Hotema
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
December 6, 2022
Date of Patent:
May 28, 2024
Assignee:
Enanta Pharmaceuticals, Inc.
Inventors:
Joseph D. Panarese, Samuel Bartlett, Yat Sun Or
Abstract: A discrete catheter assembly as provided includes a containment unit and an outer protector layer. The outer protector layer has a rear cap, which is fitted over the shell base of the outer protector layer in which the front cap of the outer protector layer is removed while the rear cap of the outer protector layer is moved in a first direction away from the dispenser, then moved in a second direction to permit a movement of the catheter of the containment unit towards the dispenser.
Type:
Application
Filed:
November 22, 2022
Publication date:
May 23, 2024
Applicant:
HR Pharmaceuticals, Inc.
Inventors:
Matt Hanna, Colby Wiesman, Chris Wiesman, Randy Golden, Sara Zebouni Miars, John Golden
Abstract: Provided are methods of treatment of abdominal pain due to IBS, comprising administering to an individual in need thereof (1aS,5aS)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((S)-1-Hydroxymethyl-2,2-dimethyl-propyl)-amide or a pharmaceutically acceptable salt or crystal form thereof.
Type:
Application
Filed:
March 1, 2022
Publication date:
May 23, 2024
Applicant:
Arena Pharmaceuticals, Inc.
Inventors:
Fabio Cataldi, Brett Alan English, Beatriz Fioravanti Lindstrom, Charlies Chunhua Liu, Sharon Diane Skare, Stewart Alleyn Turner
Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.
Type:
Application
Filed:
November 6, 2023
Publication date:
May 23, 2024
Applicant:
Fennec Pharmaceuticals Inc.
Inventors:
Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
Abstract: The present disclosure provides phenalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods of making various phenalkylamine compounds are provided.
Abstract: Methods for producing high concentration protein formulations having high stability are provided. Assays for selecting proteins and formulation conditions that have high self-repulsive attributes are used as an early step in the manufacturing process. Specifically, a protein concentration-dependent self-interaction nanoparticle spectroscopy method is employed as a protein colloidal interaction assay.
Type:
Grant
Filed:
July 20, 2022
Date of Patent:
May 21, 2024
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Michael Marlow, Michael Sennett, Michael Schneider
Abstract: A chewable pharmaceutical product comprises a matrix comprising: a binder, a bulking agent, a lubricant, a humectant, an emulsifier, and optionally a flavoring, wherein the binder comprises one or more maltitol syrups, which are present in the pharmaceutical product in an amount in the range of 60-70% by weight; and colesevelam hydrochloride.
Abstract: Disclosed herein are methods for treating acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. The method includes administering to a subject in need of treatment a therapeutically effective amount of inorganic nitrite. The nitrite may be administered by inhalation and may be nebulized. The nitrite may be administered at an emitted dose or in an escalated titrated dose. The nitrite may be a liquid formulation or a dry powder formulation.
Type:
Grant
Filed:
December 2, 2021
Date of Patent:
May 21, 2024
Assignees:
University of Pittsburgh—Of the Commonwealth System of Higher Education, Aires Pharmaceuticals, Inc.
Inventors:
Mark Thomas Gladwin, Edwin Parsley, Hunter Clay Champion
Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LECT2 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of LECT2.
Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen are disclosed. Methods of treating a subject with a mesothelin-expressing tumor and methods of preventing a mesothelin-expressing tumor are disclosed. Modified consensus mesothelin antigen is disclosed.
Type:
Grant
Filed:
September 7, 2021
Date of Patent:
May 21, 2024
Assignee:
Inovio Pharmaceuticals, Inc.
Inventors:
Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure and related disorders thereto.
Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.
Type:
Grant
Filed:
December 22, 2023
Date of Patent:
May 21, 2024
Assignees:
Madrigal Pharmaceuticals, Inc., Hoffmann-La Roche Inc.
Inventors:
Martha J. Kelly, Rebecca Taub, Edward Hung Yang Chiang